Screener / SEC EDGAR /CIK 0001757073 /10-K filed Feb 12, 2026, compared with Feb 13, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Health care · Dental Equipment & Supplies

Envista Holdings Corp NVST

Compare with peers Embed
Earnings releases

Latest results release: Nov 4, 2026

8-K item 2.02, exhibit 99

What NVST's management wrote with each quarter's results: the press release and, when the company files them, its prepared remarks or the call transcript. The call itself is not filed with SEC, so most quarters have the release only.

Adjusted vs GAAP earnings per share

In the company's own words · read from each release, never computed

In its release of Nov 4, 2026, NVST reported $3.11 per share under GAAP and $0.40 on its own adjusted basis: the adjusted number is -87% below GAAP.

GAAP EPS $0.16, release Jul 31, 2025: EPS of $0.16 and adjusted EPS of $0.26 (+136% year-on-year) ■ H1 2025 highlights: Adjusted EPS $0.26, release Jul 31, 2025: EPS of $0.16 and adjusted EPS of $0.26 (+136% year-on-year) ■ H1 2025 highlights: +62% 2025-07 GAAP EPS $-0.18, release Oct 29, 2025: GAAP EPS of ($0.18) and adjusted EPS of $0.32 (+167% year-on-year) Adjusted EPS $0.32, release Oct 29, 2025: GAAP EPS of ($0.18) and adjusted EPS of $0.32 (+167% year-on-year) 2025-10 GAAP EPS $0.20, release Feb 5, 2026: GAAP diluted EPS of $0.20 and adjusted diluted EPS of $0.38 (+58% year-on- year) Adjusted EPS $0.38, release Feb 5, 2026: GAAP diluted EPS of $0.20 and adjusted diluted EPS of $0.38 (+58% year-on- year) +90% 2026-02 GAAP EPS $0.23, release May 6, 2026: GAAP diluted EPS of $0.23 and adjusted diluted EPS of $0.36 (+50% year-on- year) Adjusted EPS $0.36, release May 6, 2026: GAAP diluted EPS of $0.23 and adjusted diluted EPS of $0.36 (+50% year-on- year) +56% 2026-05 GAAP EPS $0.33, release Aug 5, 2026: GAAP diluted EPS of $0.33 and adjusted diluted EPS of $0.41 (+58% year-on- year) Adjusted EPS $0.41, release Aug 5, 2026: GAAP diluted EPS of $0.33 and adjusted diluted EPS of $0.41 (+58% year-on- year) +24% 2026-08 GAAP EPS $3.11, release Nov 4, 2026: GAAP diluted EPS of $3.11 and adjusted diluted EPS of $0.40 (+25% year-over- year) Adjusted EPS $0.40, release Nov 4, 2026: GAAP diluted EPS of $3.11 and adjusted diluted EPS of $0.40 (+25% year-over- year) -87% 2026-11
GAAP EPSAdjusted EPS, as the company defines itThe figure on top is how far adjusted is from GAAP. Click a bar for the sentence.
ReleaseGAAP EPSAdjusted EPSGap
Nov 4, 2026 3.11 0.40 -87%
Aug 5, 2026 0.33 0.41 +24%
May 6, 2026 0.23 0.36 +56%
Feb 5, 2026 0.20 0.38 +90%
Oct 29, 2025 -0.18 0.32 –
Jul 31, 2025 0.16 0.26 +62%
The company's words, latest release
GAAP diluted EPS of $3.11 and adjusted diluted EPS of $0.40 (+25% year-over- year) release

What the company says its adjusted numbers leave out:

◦ With respect to the other items excluded from Adjusted Gross Profit, Adjusted Net Income, Adjusted Operating Profit, Adjusted Diluted Earnings Per Share and Adjusted EBITDA, we exclude these items because they are of a nature and/or size that occur with inconsistent frequency, occur for reasons that may be unrelated to Envista's commercial performance during the period and/or we believe that such items may obscure underlying business trends and make comparisons of long- term performance difficult. release Nov 4, 2026

Both numbers are read from the words of each release (usually the highlights), never computed by us; hover a number for its sentence. Quarters where the release gives them only in a table are not shown. The company decides what "adjusted" leaves out; the full reconciliation is in the release.

Read and search

Every release, in full · linked to sec.gov

Press release Nov 4, 2026 · EX-99.1

Envista Reports Third Quarter 2026 Results

Open on SEC

BREA, Calif., November 4, 2026 / PRNewswire / -- Envista Holdings Corporation (NYSE: NVST) today announced results for the quarter ended October 2, 2026.

“Envista delivered another quarter of profitable growth, gaining share and expanding margins,” said Paul Keel, CEO. “Supported by the Envista Business System, we are converting broad-based topline performance into even stronger earnings growth, while continuing to invest in our customers, colleagues and communities to sustain long-term success. Our strong momentum and year-to-date progress give us confidence to raise our full-year earnings guidance once again.”

• Sales were $691 million, with core sales growth of 2.7% over the third quarter of 2025

• GAAP diluted EPS of $3.11 and adjusted diluted EPS of $0.40 (+25% year-over- year)

• GAAP net income of $508 million and adjusted EBITDA of $106 million (+9% year- over-year), with an adjusted EBITDA margin of 15.3% (+80 bps year-over-year)

• Growth: Both reporting segments delivered positive core sales growth, with 2.0% core sales growth in Specialty Products & Technologies and 4.1% core sales growth in Equipment & Consumables.

• Operations: Ongoing contributions from the Envista Business System (EBS) contributed to year-over-year adjusted gross margin expansion of 20 bps, with adjusted EBITDA margin up 80 bps.

• People: We published our 2025 Sustainability Report, opened a new European Design Center for Spark, and continued to make lasting positive impact in our communities through the Envista Smile Project.

In the quarter we recognized a foreign currency translation gain resulting in $428 million in operating profit and $2.62 of diluted EPS, before associated tax effects. This gain reflects the release of cumulative translation adjustments associated with the dissolution of certain legal entities as part of our legal entity simplification efforts. This gain had no cash impact and no impact on adjusted EBITDA, adjusted operating income, or adjusted diluted EPS.

Operating cash flow for the third quarter of 2026 was $78 million and free cash flow was $63 million, compared to $79 million and $68 million in the third quarter of 2025, respectively.

During the quarter ended October 2, 2026, we repurchased 386 thousand shares for approximately $10 million. At the end of the quarter, we had approximately $273 million of remaining repurchase capacity under our stock repurchase program. 1 Outlook:

Updated 2026 Guidance Prior 2026 Guidance Core Sales Growth 3.75% to 4.25% 3.5% to 4.5% Adjusted EBITDA Growth 12.5% to 14% 11% to 14% Adjusted Diluted Earnings $1.54 to $1.58 $1.50 to $1.55 Per Share Free Cash Flow Conversion ~100% ~100%

Please note, we do not provide forward-looking estimates on a GAAP basis as certain information is not available and cannot be reasonably estimated.

We will discuss our quarterly results and provide details on our outlook for 2026 during an investor conference call on November 4, 2026, starting at 2:00 p.m. PT. The call and an accompanying slide presentation will be webcast on the “ Investors ” section of our website, www.envistaco.com , under the subheading “ Events & Presentations. ” A replay of the webcast will be available in the same section of our website shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call.

The conference call can be accessed by dialing 800-836-8184 within the U.S. or +1 646-357-8785 outside the U.S. a few minutes before 2:00 p.m. PT and referencing conference ID #21785. A replay of the conference call will be available shortly after the conclusion of the call. You can access the replay dial-in information on the “ Investors ” section of our website under the subheading “ Events & Presentations. ” Presentation materials relating to our results have been posted to the “ Investors ” section of our website under the subheading “ Quarterly Earnings ” .

Envista is a global leader in the dental industry, uniting more than 30 trusted brands—including DEXIS, Kerr, Nobel Biocare, and Ormco—under one mission: partnering with dental professionals to improve patients’ lives. With a heritage of category-defining innovation, our brands have shaped modern dentistry: Nobel Biocare introduced the first dental implant, Ormco is a pioneer in both traditional and digital orthodontics, DEXIS has long been at the forefront of 2D, 3D and intraoral imaging, and Kerr has supported clinicians for over 135 years. Our high-performing culture is underpinned by our CIRCLe Values and the Envista Business System. Guided by these, we deliver a comprehensive portfolio of technologies, consumables, and services that empower clinicians to provide confident, efficient care—today and for the future. Learn more at http://envistaco.com . 2

All Adjusted amounts including core sales growth and free cash flow are non-GAAP items. Calculations of these measures, the reasons why we believe these measures provide useful information to investors, a reconciliation of these measures to the most directly comparable GAAP measures, and other information relating to these non-GAAP measures are included in the attached supplemental schedules. We do not reconcile forward-looking non-GAAP measures to the comparable GAAP measures because of the inherent difficulty in predicting and estimating the future impact and timing of currency translation, acquisitions, discontinued products, and any other potential adjustments which would be reflected in any forecasted GAAP measure.

Certain statements in this press release are forward-looking statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among other things, the conditions in the U.S. and global economy, the impact of inflation and increasing interest rates, slower economic growth or recession, international economic, political, legal, compliance and business factors, the markets served by us and the financial markets, the impact of our debt obligations on our operations and liquidity, developments and uncertainties in trade policies and regulations including tariffs or other impositions on imported goods, contractions or growth rates and cyclicality of markets we serve, risks relating to product manufacturing, commodity costs and surcharges, our ability to adjust purchases and manufacturing capacity to reflect market conditions, reliance on sole or limited sources of supply, disruptions relating to war (including supply chain disruptions), terrorism, climate change, widespread protests and civil unrest, man-made and natural disasters, public health issues and other events, security breaches or other disruptions of our information technology systems or violations of data privacy laws, security breaches or other disruptions affecting our external information technology contractors, vendors or other service providers, our growing use of artificial intelligence systems to automate processes and analyze data, fluctuations in inventory of our distributors and customers, loss of a key distributor, our relationships with and the performance of our channel partners, competition, our ability to develop and successfully market new products and services, our ability to attract, develop and retain our key personnel, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and regulations (including regulations relating to medical devices and the health care industry), the results of our clinical trials and perceptions thereof, penalties associated with any off-label marketing of our products, modifications to our products that require new marketing clearances or authorizations, our ability to effectively address cost reductions and other changes in the health care industry, our ability to successfully identify and consummate appropriate acquisitions and strategic investments, our ability to integrate the businesses we acquire and achieve the anticipated benefits of such acquisitions, contingent liabilities relating to acquisitions, investments and divestitures, our ability to adequately protect our intellectual property, the impact of our restructuring activities on our ability to grow, risks relating to impairment charges for our goodwill and intangible assets, changes in accounting standards and subjective assumptions, estimates and judgment by management, currency exchange rates, changes in tax laws applicable to multinational companies, litigation and other contingent liabilities including intellectual property and environmental, health and safety matters, risks relating to product, service or software defects, the impact of regulation on demand for our products and services, and labor matters. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our Annual Report on Form 10-K for fiscal year 2025 and our Quarterly reports on Form 10-Q. These forward-looking statements speak only as of the date of this press release and except to the extent required by applicable law, we do not assume any obligation to update or revise any forward- looking statement, whether as a result of new information, future events and developments or otherwise.

As of October 2, 2026 December 31, 2025 ────────────────────────────────────────────────────────────────────────────── ASSETS Current assets: Cash and cash equivalents $ 1,158.8 $ 1,211.7 Trade accounts receivable, less allowance for credit 448.5 429.6 losses of $23.2 and $22.5, respectively Inventories, net 285.2 288.1 Prepaid expenses and other current 109.3 97.2 assets Total current assets 2,001.8 2,026.6 Property, plant and 300.7 296.8 equipment, net Operating lease 153.4 142.1 right-of-use assets Other long-term assets 218.4 228.1 Goodwill 2,343.4 2,358.2 Other intangible assets, 593.3 627.2 net Total assets $ 5,611.0 $ 5,679.0 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Trade accounts payable 171.8 191.6 Accrued expenses and other 606.6 622.0 liabilities Operating lease 37.9 39.0 liabilities Total current liabilities 816.3 852.6 Operating lease 120.6 110.4 liabilities Other long-term 156.5 161.4 liabilities Long-term debt 1,429.0 1,448.3 Commitments and contingencies Stockholders’ equity: Preferred stock, $0.01 par value, 15.0 million shares authorized; no shares — — issued or outstanding at October 2, 2026 and December 31, 2025 Common stock, $0.01 par value, 500.0 million shares authorized; 176.6 million shares issued and 160.3 million shares 1.8 1.8 outstanding at October 2, 2026; 175.4 million shares issued and 163.8 million shares outstanding at December 31, 2025 Treasury stock at cost; 16.3 million shares and 11.6 million shares at -344.7 -224.5 October 2, 2026 and December 31, 2025, respectively Additional paid-in capital 3,917.5 3,882.6 Retained earnings 160.3 -440.4 (accumulated deficit) Accumulated other -646.3 -113.2 comprehensive loss Total stockholders’ equity 3,088.6 3,106.3 Total liabilities and stockholders’ $ 5,611.0 $ 5,679.0 equity

September 26, Nine Months Ended October 2, 2026 2025 ────────────────────────────────────────────────────────────────────────────── Cash flows from operating activities: Net income $ 600.7 $ 14.1 Noncash items: Depreciation 31.2 30.0 Amortization 51.2 56.9 Allowance for 12.4 6.0 credit losses Stock-based compensation 29.5 27.2 expense Gain on realized cumulative -428.1 — foreign currency translation Gain on investments in -2.3 -3.0 rabbi trust, net Loss on equity 9.6 — investments (Gain) loss on sale of -2.4 0.3 property, plant and equipment Restructuring 1.0 — charges Fixed assets impairments and 1.5 2.2 other charges Non-cash operating lease 28.0 25.8 costs Amortization of debt discount 2.9 3.2 and issuance costs Deferred income — 25.4 taxes Change in trade accounts -37.0 -23.6 receivable Change in 1.2 -34.6 inventories Change in trade accounts -19.1 -25.9 payable Change in prepaid expenses and -14.6 1.5 other assets Change in accrued expenses and -36.3 95.0 other liabilities Change in operating lease -35.6 -32.8 liabilities Net cash provided by 193.8 167.7 operating activities Cash flows from investing activities: Payments for additions to property, -43.5 -29.0 plant and equipment Purchases of investments -12.3 -9.6 held in rabbi trust Proceeds from sale of investments 10.6 9.9 held in rabbi trust Proceeds from sales of 2.6 0.5 property, plant and equipment Acquisitions, net of cash -54.3 — acquired All other investing 0.6 -7.4 activities, net Net cash used in investing -96.3 -35.6 activities Cash flows from financing activities: Proceeds from stock option 5.3 2.5 exercises Cash paid for treasury stock under the -113.0 -142.3 stock repurchase program Treasury stock purchases related to tax -7.8 -5.0 withholding on equity awards Principal paid related to exchange of — -116.3 convertible notes due 2025 Proceeds from revolving line — 115.4 of credit All other financing -0.4 — activities Net cash used in financing -115.9 -145.7 activities Effect of exchange rate changes on cash -34.5 78.4 and cash equivalents Net change in cash and cash -52.9 64.8 equivalents Beginning balance of cash 1,211.7 1,069.1 and cash equivalents Ending balance of cash and $ 1,158.8 $ 1,133.9 cash equivalents

* For information on non-GAAP measures see “ Reconciliation of GAAP to Non-GAAP Financial Measures ” below. Also see the accompanying “ Notes to Reconciliation of GAAP to Non-GAAP Financial Measures. ” 7

See the accompanying Notes to Reconciliation of GAAP to Non-GAAP Financial Measures

See the accompanying Notes to Reconciliation of GAAP to Non-GAAP Financial Measures

% Change Three % Change Nine Month Period Month Period Ended October 2, Ended October 2026 vs. 2, 2026 vs. Comparable 2025 Comparable 2025 Consolidated Period Period ────────────────────────────────────────────────────────────────────────────── Total sales 3.2 % 8.1 % growth Plus the impact of: Acquisitions -0.5 % -0.5 % Currency — % -2.0 % exchange rates Core Sales 2.7 % 5.6 % Growth Specialty Products & Technologies Total sales 2.8 % 7.5 % growth Plus the impact of: Acquisitions -0.8 % -0.8 % Currency — % -2.3 % exchange rates Core Sales 2.0 % 4.4 % Growth Equipment & Consumables Total sales 3.9 % 9.1 % growth Plus the impact of: Currency 0.2 % -1.2 % exchange rates Core Sales 4.1 % 7.9 % Growth

1 We use the term “core sales” to refer to GAAP revenue excluding (1) sales from acquired businesses recorded prior to the first anniversary of the acquisition (“acquisitions”), (2) sales from discontinued products and (3) the impact of currency translation. Sales from discontinued products includes major brands or products that Envista has made the decision to discontinue as part of a portfolio restructuring. Discontinued brands or products consist of those which Envista (1) is no longer manufacturing, (2) is no longer investing in the research or development of, and (3) expects to discontinue all significant sales within one year from the decision date to discontinue. The portion of sales attributable to discontinued brands or products is calculated as the net decline of the applicable discontinued brand or product from period-to-period. The portion of GAAP revenue attributable to currency exchange rates is calculated as the difference between (a) the period-to-period change in sales and (b) the period-to-period change in sales after applying current period foreign exchange rates to the prior year period. We use the term “core sales growth” to refer to the measure of comparing current period core sales with the corresponding period of the prior year.

During the first quarter of 2026, we updated our methodology for how we calculate changes in the sales price from period to period. Changes in sales prices are now calculated by comparing the current quarter sales prices to the full year sales price average from the prior year as it better reflects pricing trends over time. 13 Reconciliation of Operating Cash Flows to Free Cash Flow

See the accompanying Notes to Reconciliation of GAAP to Non-GAAP Financial Measures

NOTES TO RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (UNAUDITED) A We exclude impairment of certain long-lived assets, executive transition costs, and cost incurred pursuant to discrete restructuring plans.

B Represents the fair value adjustment related to inventory acquired in connection with acquisitions.

C Represents the U.S. Supreme Court's ruling to refund tariffs imposed under the International Emergency Economic Powers Act.

E Represents acquisition-related transaction expenses and integration costs with respect to business combinations.

F Represents the release of cumulative translation adjustments related to the dissolution of certain legal entities.

H This line item represents the aggregate tax effect of all pretax adjustments reflected in the preceding line items of the table using each adjustment's applicable tax rate, including the effect of interim tax accounting requirements of Accounting Standards Codification Topic 740 Income Taxes.

I Discrete tax matters primarily relate to excess tax benefits from stock-based compensation, changes in estimates associated with prior period uncertain tax positions and audit settlements, tax benefits resulting from a change in law, and changes in determination of realization of certain deferred tax assets.

J The Company was in a net loss position for the three months ended September 26, 2025, therefore no shares reserved for issuance upon exercise of stock options, or vesting of restricted stock and performance stock units were included in the computation of diluted loss per share as their inclusion would have been anti-dilutive. However, given that the adjustments noted in footnotes A-I resulted in adjusted net income for the three months ended September 26, 2025, the dilutive impact of stock options and restricted stock and performance stock units are being included to arrive at adjusted diluted shares outstanding.

Each of the non-GAAP measures set forth above should be considered in addition to, and not as a replacement for or superior to, the comparable GAAP measure, and may not be comparable to similarly titled measures reported by other companies. Management believes that these measures provide useful information to investors by offering additional ways of viewing Envista Holdings Corporation's (“Envista” or the “Company”) results that, when reconciled to the corresponding GAAP measure, help our investors to:

• with respect to Core Sales, identify underlying growth trends in Envista’s business and compare Envista’s revenue performance with prior and future periods and to Envista’s peers;

• with respect to Adjusted Gross Profit, Adjusted Operating Profit, Adjusted Net Income, Adjusted Diluted Earnings Per Share and Adjusted EBITDA, understand the long-term profitability trends of Envista’s business and compare Envista’s profitability to prior and future periods and to Envista’s peers;

• with respect to Adjusted EBITDA, understand operational factors associated with Envista’s financial performance because it excludes the following from consideration: interest, taxes, depreciation, amortization, and infrequent or unusual losses or gains such as goodwill impairment charges or nonrecurring items and restructuring charges. Management uses Adjusted EBITDA, as a supplemental measure for assessing operating performance in conjunction with related GAAP amounts. In addition, Adjusted EBITDA is used in connection with operating decisions, strategic planning, annual budgeting, evaluating Company performance and comparing operating results with historical periods and with industry peer companies; and 15 • with respect to Free Cash Flow (the “FCF Measure”), understand Envista’s ability to generate cash without external financings, in order to invest and grow its business through acquisitions and other strategic opportunities. A limitation of free cash flow is that it does not take into account the Company’s debt service requirements and other non-discretionary expenditures, and as a result the entire Free Cash Flow amount is not necessarily available for discretionary expenditures.

Management uses these non-GAAP measures to evaluate the Company’s operating and financial performance.

The items excluded from the non-GAAP measures set forth above have been excluded for the following reasons:

• With respect to Adjusted Gross Profit, Adjusted Operating Profit, Adjusted Net Income, Adjusted Diluted Earnings Per Share and Adjusted EBITDA:

◦ We exclude amortization of acquisition-related and other intangible assets because the amount and timing of such charges are significantly impacted by the timing, size, number and nature of the acquisitions we consummate. While we have a history of significant acquisition activity, we do not acquire businesses on a predictable cycle, and the amount of an acquisition’s purchase price allocated to intangible assets and related amortization term are unique to each acquisition and can vary significantly from acquisition to acquisition. Exclusion of this amortization expense facilitates more consistent comparisons of operating results over time between our newly acquired and long-held businesses, and with both acquisitive and non-acquisitive peer companies. We believe, however, that it is important for investors to understand that such intangible assets contribute to revenue generation and that intangible asset amortization related to past acquisitions will recur in future periods until such intangible assets have been fully amortized.

◦ With respect to the other items excluded from Adjusted Gross Profit, Adjusted Net Income, Adjusted Operating Profit, Adjusted Diluted Earnings Per Share and Adjusted EBITDA, we exclude these items because they are of a nature and/or size that occur with inconsistent frequency, occur for reasons that may be unrelated to Envista's commercial performance during the period and/or we believe that such items may obscure underlying business trends and make comparisons of long- term performance difficult.

• With respect to core sales, we exclude (1) the effect of acquisitions and divested product lines because the timing, size, number and nature of such transactions can vary significantly from period-to-period and between us and our peers, which we believe may obscure underlying business trends and make comparisons of long-term performance difficult, (2) sales from discontinued products because discontinued products do not have a continuing contribution to operations and management believes that excluding such items provides investors with a means of evaluating our on-going operations and facilitates comparisons to our peers, and (3) the impact of currency translation because it is not under management’s control, is subject to volatility and can obscure underlying business trends.

• With respect to the FCF Measure, we adjust for payments for additions to property, plant and equipment (net of the proceeds from capital disposals) to arrive at the amount of operating cash flow for the period that remains after accounting for the Company’s capital expenditure requirements. 16

Full text with the tables
                                                                    Exhibit 99.1
                                                                                
  Envista Reports Third Quarter 2026 Results                                    
                                                                                
BREA, Calif., November 4, 2026 / PRNewswire / -- Envista Holdings Corporation
(NYSE: NVST) today announced results for the quarter ended October 2, 2026.

“Envista delivered another quarter of profitable growth, gaining share and
expanding margins,” said Paul Keel, CEO. “Supported by the Envista Business
System, we are converting broad-based topline performance into even stronger
earnings growth, while continuing to invest in our customers, colleagues and
communities to sustain long-term success. Our strong momentum and year-to-date
progress give us confidence to raise our full-year earnings guidance once
again.”
                                                                                
  Third Quarter Financial Highlights                                            
                                                                                
• Sales were $691 million, with core sales growth of 2.7% over the third quarter
of 2025

• GAAP diluted EPS of $3.11 and adjusted diluted EPS of $0.40 (+25% year-over-
year)

• GAAP net income of $508 million and adjusted EBITDA of $106 million (+9% year-
over-year), with an adjusted EBITDA margin of 15.3% (+80 bps year-over-year)
                                                                                
  Third Quarter Business Highlights                                             
                                                                                
• Growth: Both reporting segments delivered positive core sales growth, with
2.0% core sales growth in Specialty Products & Technologies and 4.1% core sales
growth in Equipment & Consumables.

• Operations: Ongoing contributions from the Envista Business System (EBS)
contributed to year-over-year adjusted gross margin expansion of 20 bps, with
adjusted EBITDA margin up 80 bps.

• People: We published our 2025 Sustainability Report, opened a new European
Design Center for Spark, and continued to make lasting positive impact in our
communities through the Envista Smile Project.
                                                                                
  Net Income, EBITDA, and EPS                                                   
                                                                                
(in millions, except per share amounts) :
                                                                                
            Three                  Septem…    Nine                              
            Months   October           26,    Months    October       Septemb…  
            Ended    2, 2026          2025    Ended     2, 2026       26, 2025  
 ────────────────────────────────────────────────────────────────────────────── 
  GAAP                                                                          
  Net       $            508    $      -30    $             601    $        14  
  Income                                                                        
  (Loss)                                                                        
  Adjus…                                                                        
  Net       $             65    $       54    $             192    $       139  
  Income                                                                        
  Adjus…    $            106    $       97    $             312    $       260  
  EBITDA                                                                        
  GAAP                                                                          
  Dilut…                                                                        
  Earni…    $           3.11    $    -0.18    $            3.65    $      0.08  
  (Loss)                                                                        
  Per                                                                           
  Share                                                                         
  Adjus…                                                                        
  Dilut…                                                                        
  Earni…    $           0.40    $     0.32    $            1.16    $      0.82  
  Per                                                                           
  Share                                                                         
                                                                                
Realized Cumulative Foreign Currency Translation Gain:

In the quarter we recognized a foreign currency translation gain resulting in
$428 million in operating profit and $2.62 of diluted EPS, before associated tax
effects. This gain reflects the release of cumulative translation adjustments
associated with the dissolution of certain legal entities as part of our legal
entity simplification efforts. This gain had no cash impact and no impact on
adjusted EBITDA, adjusted operating income, or adjusted diluted EPS.

Cash Flow:

Operating cash flow for the third quarter of 2026 was $78 million and free cash
flow was $63 million, compared to $79 million and $68 million in the third
quarter of 2025, respectively.

Share Repurchases:

During the quarter ended October 2, 2026, we repurchased 386 thousand shares for
approximately $10 million. At the end of the quarter, we had approximately $273
million of remaining repurchase capacity under our stock repurchase program.
                                       1                                        
Outlook:

We are updating our guidance for the full year 2026:
                                                                                
                                  Updated 2026 Guidance    Prior 2026 Guidance  
  Core Sales Growth               3.75% to 4.25%           3.5% to 4.5%         
  Adjusted EBITDA Growth          12.5% to 14%             11% to 14%           
  Adjusted Diluted Earnings       $1.54 to $1.58           $1.50 to $1.55       
  Per Share                                                                     
  Free Cash Flow Conversion       ~100%                    ~100%                
                                                                                
Please note, we do not provide forward-looking estimates on a GAAP basis as
certain information is not available and cannot be reasonably estimated.

We will discuss our quarterly results and provide details on our outlook for
2026 during an investor conference call on November 4, 2026, starting at 2:00
p.m. PT. The call and an accompanying slide presentation will be webcast on the
“ Investors ” section of our website, www.envistaco.com , under the subheading “
Events & Presentations. ” A replay of the webcast will be available in the same
section of our website shortly after the conclusion of the presentation and will
remain available until the next quarterly earnings call.

The conference call can be accessed by dialing 800-836-8184 within the U.S. or
+1 646-357-8785 outside the U.S. a few minutes before 2:00 p.m. PT and
referencing conference ID #21785. A replay of the conference call will be
available shortly after the conclusion of the call. You can access the replay
dial-in information on the “ Investors ” section of our website under the
subheading “ Events & Presentations. ” Presentation materials relating to our
results have been posted to the “ Investors ” section of our website under the
subheading “ Quarterly Earnings ” .
                                                                                
  ABOUT ENVISTA                                                                 
                                                                                
Envista is a global leader in the dental industry, uniting more than 30 trusted
brands—including DEXIS, Kerr, Nobel Biocare, and Ormco—under one mission:
partnering with dental professionals to improve patients’ lives. With a heritage
of category-defining innovation, our brands have shaped modern dentistry: Nobel
Biocare introduced the first dental implant, Ormco is a pioneer in both
traditional and digital orthodontics, DEXIS has long been at the forefront of
2D, 3D and intraoral imaging, and Kerr has supported clinicians for over 135
years. Our high-performing culture is underpinned by our CIRCLe Values and the
Envista Business System. Guided by these, we deliver a comprehensive portfolio
of technologies, consumables, and services that empower clinicians to provide
confident, efficient care—today and for the future. Learn more at
http://envistaco.com .
                                       2                                        
                                                                                
  NON-GAAP MEASURES                                                             
                                                                                
All Adjusted amounts including core sales growth and free cash flow are non-GAAP
items. Calculations of these measures, the reasons why we believe these measures
provide useful information to investors, a reconciliation of these measures to
the most directly comparable GAAP measures, and other information relating to
these non-GAAP measures are included in the attached supplemental schedules. We
do not reconcile forward-looking non-GAAP measures to the comparable GAAP
measures because of the inherent difficulty in predicting and estimating the
future impact and timing of currency translation, acquisitions, discontinued
products, and any other potential adjustments which would be reflected in any
forecasted GAAP measure.
                                                                                
  FORWARD-LOOKING STATEMENTS                                                    
                                                                                
Certain statements in this press release are forward-looking statements within
the meaning of the federal securities laws. There are a number of important
factors that could cause actual results, developments and business decisions to
differ materially from those suggested or indicated by such forward-looking
statements and you should not place undue reliance on any such forward-looking
statements. These factors include, among other things, the conditions in the
U.S. and global economy, the impact of inflation and increasing interest rates,
slower economic growth or recession, international economic, political, legal,
compliance and business factors, the markets served by us and the financial
markets, the impact of our debt obligations on our operations and liquidity,
developments and uncertainties in trade policies and regulations including
tariffs or other impositions on imported goods, contractions or growth rates and
cyclicality of markets we serve, risks relating to product manufacturing,
commodity costs and surcharges, our ability to adjust purchases and
manufacturing capacity to reflect market conditions, reliance on sole or limited
sources of supply, disruptions relating to war (including supply chain
disruptions), terrorism, climate change, widespread protests and civil unrest,
man-made and natural disasters, public health issues and other events, security
breaches or other disruptions of our information technology systems or
violations of data privacy laws, security breaches or other disruptions
affecting our external information technology contractors, vendors or other
service providers, our growing use of artificial intelligence systems to
automate processes and analyze data, fluctuations in inventory of our
distributors and customers, loss of a key distributor, our relationships with
and the performance of our channel partners, competition, our ability to develop
and successfully market new products and services, our ability to attract,
develop and retain our key personnel, the potential for improper conduct by our
employees, agents or business partners, our compliance with applicable laws and
regulations (including regulations relating to medical devices and the health
care industry), the results of our clinical trials and perceptions thereof,
penalties associated with any off-label marketing of our products, modifications
to our products that require new marketing clearances or authorizations, our
ability to effectively address cost reductions and other changes in the health
care industry, our ability to successfully identify and consummate appropriate
acquisitions and strategic investments, our ability to integrate the businesses
we acquire and achieve the anticipated benefits of such acquisitions, contingent
liabilities relating to acquisitions, investments and divestitures, our ability
to adequately protect our intellectual property, the impact of our restructuring
activities on our ability to grow, risks relating to impairment charges for our
goodwill and intangible assets, changes in accounting standards and subjective
assumptions, estimates and judgment by management, currency exchange rates,
changes in tax laws applicable to multinational companies, litigation and other
contingent liabilities including intellectual property and environmental, health
and safety matters, risks relating to product, service or software defects, the
impact of regulation on demand for our products and services, and labor matters.
Additional information regarding the factors that may cause actual results to
differ materially from these forward-looking statements is available in our SEC
filings, including our Annual Report on Form 10-K for fiscal year 2025 and our
Quarterly reports on Form 10-Q. These forward-looking statements speak only as
of the date of this press release and except to the extent required by
applicable law, we do not assume any obligation to update or revise any forward-
looking statement, whether as a result of new information, future events and
developments or otherwise.
                                                                                
  CONTACT                                                                       
                                                                                
Jim Gustafson

Vice President, Investor Relations

Envista Holdings Corporation

200 S. Kraemer Blvd., Building E

Brea, CA 92821

[email protected]
                                       3                                        
                                                                                
                          ENVISTA HOLDINGS CORPORATION                          
                                                                                
                                                                                
          CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)           
                                                                                
              ($ and shares in millions, except per share amounts)              
                                                                                
            Three                  Septem…    Nine                              
            Months   October           26,    Months    October       Septemb…  
            Ended    2, 2026          2025    Ended     2, 2026       26, 2025  
 ────────────────────────────────────────────────────────────────────────────── 
  Sales     $          691.5    $    669.9    $         2,127.5    $   1,968.9  
  Cost                                                                          
  of                   290.9         299.7                929.8          892.8  
  sales                                                                         
  Gross                400.6         370.2              1,197.7        1,076.1  
  profit                                                                        
  Opera…                                                                        
  expen…                                                                        
  (inco…                                                                        
  Selli…                                                                        
  gener…               284.2         284.4                878.1          851.4  
  and                                                                           
  admin…                                                                        
  Resea…                                                                        
  and                   29.3          28.3                 89.7           81.9  
  devel…                                                                        
  Reali…                                                                        
  cumul…                                                                        
  forei…              -428.1             —               -428.1              —  
  curre…                                                                        
  trans…                                                                        
  gain                                                                          
  Opera…               515.2          57.5                658.0          142.8  
  profit                                                                        
  Nonop…                                                                        
  (expe…                                                                        
  incom…                                                                        
  Other                                                                         
  (expe…                -7.2           1.4                 -7.3            3.1  
  incom…                                                                        
  net                                                                           
  Inter…                                                                        
  expen…                -7.8          -9.0                -23.9          -26.3  
  net                                                                           
  Income                                                                        
  before               500.2          49.9                626.8          119.6  
  income                                                                        
  taxes                                                                         
  Income                                                                        
  tax                   -8.1          80.2                 26.1          105.5  
  (bene…                                                                        
  expen…                                                                        
  Net                                                                           
  income    $          508.3    $    -30.3    $           600.7    $      14.1  
  (loss)                                                                        
  Earni…                                                                        
  (loss)                                                                        
  per                                                                           
  share:                                                                        
  Earni…                                                                        
  (loss)    $           3.16    $    -0.18    $            3.70    $      0.08  
  -                                                                             
  basic                                                                         
  Earni…                                                                        
  (loss)    $           3.11    $    -0.18    $            3.65    $      0.08  
  -                                                                             
  dilut…                                                                        
  Avera…                                                                        
  common                                                                        
  stock                                                                         
  and                                                                           
  common                                                                        
  equiv…                                                                        
  shares                                                                        
  outst…                                                                        
  Basic                160.8         166.1                162.2          169.2  
  Dilut…               163.4         166.1                164.7          170.3  
                                                                                
                                       4                                        
                                                                                
                          ENVISTA HOLDINGS CORPORATION                          
                                                                                
                                                                                
               CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)                
                                                                                
                     ($ in millions, except share amounts)                      
                                                                                
                                As of  October 2, 2026       December 31, 2025  
 ────────────────────────────────────────────────────────────────────────────── 
  ASSETS                                                                        
  Current assets:                                                               
  Cash and cash equivalents     $              1,158.8    $            1,211.7  
  Trade accounts receivable,                                                    
  less                                                                          
  allowance for credit                           448.5                   429.6  
  losses of $23.2 and                                                           
  $22.5, respectively                                                           
  Inventories, net                               285.2                   288.1  
  Prepaid expenses and other                                                    
  current                                        109.3                    97.2  
  assets                                                                        
  Total current assets                         2,001.8                 2,026.6  
  Property, plant and                            300.7                   296.8  
  equipment, net                                                                
  Operating lease                                153.4                   142.1  
  right-of-use assets                                                           
  Other long-term assets                         218.4                   228.1  
  Goodwill                                     2,343.4                 2,358.2  
  Other intangible assets,                       593.3                   627.2  
  net                                                                           
  Total assets                  $              5,611.0    $            5,679.0  
  LIABILITIES AND                                                               
  STOCKHOLDERS’ EQUITY                                                          
  Current liabilities:                                                          
  Trade accounts payable                         171.8                   191.6  
  Accrued expenses and other                     606.6                   622.0  
  liabilities                                                                   
  Operating lease                                 37.9                    39.0  
  liabilities                                                                   
  Total current liabilities                      816.3                   852.6  
  Operating lease                                120.6                   110.4  
  liabilities                                                                   
  Other long-term                                156.5                   161.4  
  liabilities                                                                   
  Long-term debt                               1,429.0                 1,448.3  
  Commitments and                                                               
  contingencies                                                                 
  Stockholders’ equity:                                                         
  Preferred stock, $0.01 par                                                    
  value, 15.0                                                                   
  million shares authorized;                                                    
  no shares                                          —                       —  
  issued or outstanding at                                                      
  October 2, 2026                                                               
  and December 31, 2025                                                         
  Common stock, $0.01 par                                                       
  value, 500.0                                                                  
  million shares authorized;                                                    
  176.6 million                                                                 
  shares issued and 160.3                                                       
  million shares                                   1.8                     1.8  
  outstanding at October 2,                                                     
  2026; 175.4                                                                   
  million shares issued and                                                     
  163.8 million                                                                 
  shares outstanding at                                                         
  December 31, 2025                                                             
  Treasury stock at cost;                                                       
  16.3 million                                                                  
  shares and 11.6 million                                                       
  shares at                                     -344.7                  -224.5  
  October 2, 2026 and                                                           
  December 31, 2025,                                                            
  respectively                                                                  
  Additional paid-in capital                   3,917.5                 3,882.6  
  Retained earnings                              160.3                  -440.4  
  (accumulated deficit)                                                         
  Accumulated other                             -646.3                  -113.2  
  comprehensive loss                                                            
  Total stockholders’ equity                   3,088.6                 3,106.3  
  Total liabilities and                                                         
  stockholders’                 $              5,611.0    $            5,679.0  
  equity                                                                        
                                                                                
                                       5                                        
                                                                                
                          ENVISTA HOLDINGS CORPORATION                          
                                                                                
          CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)           
                                                                                
                                ($ in millions)                                 
                                                                                
                                                                 September 26,  
                     Nine Months Ended  October 2, 2026                   2025  
 ────────────────────────────────────────────────────────────────────────────── 
  Cash flows from                                                               
  operating                                                                     
  activities:                                                                   
  Net income         $                            600.7    $              14.1  
  Noncash items:                                                                
  Depreciation                                     31.2                   30.0  
  Amortization                                     51.2                   56.9  
  Allowance for                                    12.4                    6.0  
  credit losses                                                                 
  Stock-based                                                                   
  compensation                                     29.5                   27.2  
  expense                                                                       
  Gain on                                                                       
  realized                                                                      
  cumulative                                     -428.1                      —  
  foreign                                                                       
  currency                                                                      
  translation                                                                   
  Gain on                                                                       
  investments in                                   -2.3                   -3.0  
  rabbi trust,                                                                  
  net                                                                           
  Loss on equity                                    9.6                      —  
  investments                                                                   
  (Gain) loss on                                                                
  sale of                                          -2.4                    0.3  
  property, plant                                                               
  and equipment                                                                 
  Restructuring                                     1.0                      —  
  charges                                                                       
  Fixed assets                                                                  
  impairments and                                   1.5                    2.2  
  other                                                                         
  charges                                                                       
  Non-cash                                                                      
  operating lease                                  28.0                   25.8  
  costs                                                                         
  Amortization of                                                               
  debt discount                                     2.9                    3.2  
  and                                                                           
  issuance costs                                                                
  Deferred income                                     —                   25.4  
  taxes                                                                         
  Change in trade                                                               
  accounts                                        -37.0                  -23.6  
  receivable                                                                    
  Change in                                         1.2                  -34.6  
  inventories                                                                   
  Change in trade                                                               
  accounts                                        -19.1                  -25.9  
  payable                                                                       
  Change in                                                                     
  prepaid                                                                       
  expenses and                                    -14.6                    1.5  
  other                                                                         
  assets                                                                        
  Change in                                                                     
  accrued                                                                       
  expenses and                                    -36.3                   95.0  
  other                                                                         
  liabilities                                                                   
  Change in                                                                     
  operating lease                                 -35.6                  -32.8  
  liabilities                                                                   
  Net cash                                                                      
  provided by                                     193.8                  167.7  
  operating                                                                     
  activities                                                                    
  Cash flows from                                                               
  investing                                                                     
  activities:                                                                   
  Payments for                                                                  
  additions to                                                                  
  property,                                       -43.5                  -29.0  
  plant and                                                                     
  equipment                                                                     
  Purchases of                                                                  
  investments                                     -12.3                   -9.6  
  held in rabbi                                                                 
  trust                                                                         
  Proceeds from                                                                 
  sale of                                                                       
  investments                                      10.6                    9.9  
  held                                                                          
  in rabbi trust                                                                
  Proceeds from                                                                 
  sales of                                          2.6                    0.5  
  property, plant                                                               
  and equipment                                                                 
  Acquisitions,                                                                 
  net of cash                                     -54.3                      —  
  acquired                                                                      
  All other                                                                     
  investing                                         0.6                   -7.4  
  activities, net                                                               
  Net cash used                                                                 
  in investing                                    -96.3                  -35.6  
  activities                                                                    
  Cash flows from                                                               
  financing                                                                     
  activities:                                                                   
  Proceeds from                                                                 
  stock option                                      5.3                    2.5  
  exercises                                                                     
  Cash paid for                                                                 
  treasury stock                                                                
  under the                                      -113.0                 -142.3  
  stock                                                                         
  repurchase                                                                    
  program                                                                       
  Treasury stock                                                                
  purchases                                                                     
  related to tax                                   -7.8                   -5.0  
  withholding on                                                                
  equity awards                                                                 
  Principal paid                                                                
  related to                                                                    
  exchange of                                         —                 -116.3  
  convertible                                                                   
  notes due 2025                                                                
  Proceeds from                                                                 
  revolving line                                      —                  115.4  
  of credit                                                                     
  All other                                                                     
  financing                                        -0.4                      —  
  activities                                                                    
  Net cash used                                                                 
  in financing                                   -115.9                 -145.7  
  activities                                                                    
  Effect of                                                                     
  exchange rate                                                                 
  changes on cash                                 -34.5                   78.4  
  and cash                                                                      
  equivalents                                                                   
  Net change in                                                                 
  cash and cash                                   -52.9                   64.8  
  equivalents                                                                   
  Beginning                                                                     
  balance of cash                               1,211.7                1,069.1  
  and cash                                                                      
  equivalents                                                                   
  Ending balance                                                                
  of cash and        $                          1,158.8    $           1,133.9  
  cash                                                                          
  equivalents                                                                   
                                                                                
                                       6                                        
                                                                                
                          ENVISTA HOLDINGS CORPORATION                          
                                                                                
                                                                                
                    SUMMARY OF FINANCIAL METRICS (Unaudited)                    
                                                                                
                   ($ in millions, except per share amounts)                    
                                                                                
            GAAP                                                                
            Three                  Septem…    Nine                              
            Months   October           26,    Months    October       Septemb…  
            Ended    2, 2026          2025    Ended     2, 2026       26, 2025  
 ────────────────────────────────────────────────────────────────────────────── 
  Gross     $          400.6    $    370.2    $         1,197.7    $   1,076.1  
  Profit                                                                        
  Opera…    $          515.2    $     57.5    $           658.0    $     142.8  
  Profit                                                                        
  Net                                                                           
  Income    $          508.3    $    -30.3    $           600.7    $      14.1  
  (Loss)                                                                        
  Dilut…                                                                        
  Earni…                                                                        
  (Loss)    $           3.11    $    -0.18    $            3.65    $      0.08  
  Per                                                                           
  Share                                                                         
  Opera…                                                                        
  Cash      $           77.9    $     78.7    $           193.8    $     167.7  
  Flow                                                                          
                                                                                
                                                                                
            NON-GA…                                                             
            *                                                                   
            Three                  Septem…    Nine                              
            Months   October           26,    Months    October       Septemb…  
            Ended    2, 2026          2025    Ended     2, 2026       26, 2025  
 ────────────────────────────────────────────────────────────────────────────── 
  Adjus…                                                                        
  Gross     $          389.5    $    375.7    $         1,185.3    $   1,085.2  
  Profit                                                                        
  Adjus…                                                                        
  Opera…    $           95.0    $     85.6    $           278.9    $     227.3  
  Profit                                                                        
  Adjus…                                                                        
  Net       $           65.2    $     53.7    $           191.7    $     138.9  
  Income                                                                        
  Adjus…                                                                        
  Dilut…    $           0.40    $     0.32    $            1.16    $      0.82  
  EPS                                                                           
  Adjus…    $          105.8    $     97.1    $           312.4    $     260.4  
  EBITDA                                                                        
  Free                                                                          
  Cash      $           63.5    $     67.9    $           152.9    $     139.2  
  Flow                                                                          
                                                                                
* For information on non-GAAP measures see “ Reconciliation of GAAP to Non-GAAP
Financial Measures ” below. Also see the accompanying “ Notes to Reconciliation
of GAAP to Non-GAAP Financial Measures. ”
                                       7                                        
                                                                                
                          ENVISTA HOLDINGS CORPORATION                          
                                                                                
                                                                                
                        SEGMENT INFORMATION (Unaudited)                         
                                                                                
                                ($ in millions)                                 
                                                                                
           Three  Octob…          Sept…       Nine    Octo…          Septe…     
           Mont…      2,            26,       Months     2,             26,     
           Ended    2026           2025       Ended    2026            2025     
 ────────────────────────────────────────────────────────────────────────────── 
  Sales                                                                         
  Spec…                                                                         
  Prod…    $       443.7       $  431.5       $       1,37…       $  1,276…     
  &                                                                             
  Tech…                                                                         
  Equi…                                                                         
  &                247.8          238.4               755.0           692.0     
  Cons…                                                                         
  Total    $       691.5       $  669.9       $       2,12…       $  1,968…     
  Oper…                                                                         
  Prof…                                                                         
  (Los…                                                                         
  Spec…                                                                         
  Prod…    $        54.3       $   48.1       $       160.9       $   131.0     
  &                                                                             
  Tech…                                                                         
  Equi…                                                                         
  &                 62.3           41.5               155.0           109.5     
  Cons…                                                                         
  Other            398.6          -32.1               342.1           -97.7     
  Total    $       515.2       $   57.5       $       658.0       $   142.8     
  Oper…                                                                         
  Marg…                                                                         
  Spec…                                                                         
  Prod…             12.2  %        11.1  %             11.7  %         10.3  %  
  &                                                                             
  Tech…                                                                         
  Equi…                                                                         
  &                 25.1  %        17.4  %             20.5  %         15.8  %  
  Cons…                                                                         
  Total             74.5  %         8.6  %             30.9  %          7.3  %  
                                                                                
                                       8                                        
                                                                                
                          ENVISTA HOLDINGS CORPORATION                          
                                                                                
       RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (UNAUDITED)        
                                                                                
              ($ and shares in millions, except per share amounts)              
                                                                                
  Adjusted Gross Profit and Adjusted Gross Margin                               
                                                                                
                                                                                
           Three  Octob…          Sept…       Nine    Octo…          Septe…     
           Mont…      2,            26,       Months     2,             26,     
           Ended    2026           2025       Ended    2026            2025     
 ────────────────────────────────────────────────────────────────────────────── 
  Gross    $       400.6       $  370.2       $       1,19…       $  1,076…     
  Prof…                                                                         
  Rest…                                                                         
  costs                                                                         
  and                3.9            4.9                14.3             7.1     
  asset                                                                         
  impa…                                                                         
  Fair                                                                          
  value                                                                         
  adju…              0.6            0.6                 1.5             2.0     
  of                                                                            
  acqu…                                                                         
  inve…                                                                         
  Tari…            -15.6              —               -28.2               —     
  refu…                                                                         
  Adju…                                                                         
  Gross    $       389.5       $  375.7       $       1,18…       $  1,085…     
  Prof…                                                                         
  Gross                                                                         
  Marg…                                                                         
  (Gro…             57.9  %        55.3  %             56.3  %         54.7  %  
  Prof…                                                                         
  /                                                                             
  Sale…                                                                         
  Adju…                                                                         
  Gross                                                                         
  Marg…                                                                         
  (Adj…             56.3  %        56.1  %             55.7  %         55.1  %  
  Gross                                                                         
  Prof…                                                                         
  /                                                                             
  Sale…                                                                         
                                                                                
                                       9                                        
Adjusted Operating Profit
                                                                                
           Three  Octob…          Sept…       Nine    Octo…          Septe…     
           Mont…      2,            26,       Months     2,             26,     
           Ended    2026           2025       Ended    2026            2025     
 ────────────────────────────────────────────────────────────────────────────── 
  Cons…                                                                         
  Oper…    $       515.2       $   57.5       $       658.0       $   142.8     
  Prof…                                                                         
  Amor…                                                                         
  of                                                                            
  acqu…                                                                         
  and               15.0           19.1                51.2            56.9     
  other                                                                         
  inta…                                                                         
  asse…                                                                         
  Rest…                                                                         
  costs                                                                         
  and                7.9            8.3                24.2            24.4     
  asset                                                                         
  impa…                                                                         
  Fair                                                                          
  value                                                                         
  adju…              0.6            0.6                 1.5             2.0     
  of                                                                            
  acqu…                                                                         
  inve…                                                                         
  Tari…            -15.6              —               -28.2               —     
  refu…                                                                         
  Liti…                —              —                   —             0.8     
  sett…                                                                         
  Acqu…                —            0.1                 0.3             0.4     
  expe…                                                                         
  Real…                                                                         
  cumu…                                                                         
  fore…           -428.1              —               -428…               —     
  curr…                                                                         
  tran…                                                                         
  gainF                                                                         
  Adju…                                                                         
  Oper…    $        95.0       $   85.6       $       278.9       $   227.3     
  Prof…                                                                         
  Adju…                                                                         
  Oper…                                                                         
  Prof…             13.7  %        12.8  %             13.1  %         11.5  %  
  as a                                                                          
  % of                                                                          
  Sales                                                                         
  Spec…                                                                         
  Prod…                                                                         
  &                                                                             
  Tech…                                                                         
  Oper…    $        54.3       $   48.1       $       160.9       $   131.0     
  Prof…                                                                         
  Amor…                                                                         
  of                                                                            
  acqu…                                                                         
  and               14.3           15.1                45.2            44.5     
  other                                                                         
  inta…                                                                         
  asse…                                                                         
  Rest…                                                                         
  costs                                                                         
  and                3.8            3.5                14.3             7.8     
  asset                                                                         
  impa…                                                                         
  Tari…             -5.7              —               -17.9               —     
  refu…                                                                         
  Adju…                                                                         
  Oper…    $        66.7       $   66.7       $       202.5       $   183.3     
  Prof…                                                                         
  Adju…                                                                         
  Oper…                                                                         
  Prof…             15.0  %        15.5  %             14.8  %         14.4  %  
  as a                                                                          
  % of                                                                          
  Sales                                                                         
  Equi…                                                                         
  &                                                                             
  Cons…                                                                         
  Oper…    $        62.3       $   41.5       $       155.0       $   109.5     
  Prof…                                                                         
  Amor…                                                                         
  of                                                                            
  acqu…                                                                         
  and                0.7            4.0                 6.0            12.4     
  other                                                                         
  inta…                                                                         
  asse…                                                                         
  Rest…                                                                         
  costs                                                                         
  and                2.4            2.4                 8.6             5.9     
  asset                                                                         
  impa…                                                                         
  Tari…             -9.9              —               -10.3               —     
  refu…                                                                         
  Liti…                —              —                   —             0.8     
  sett…                                                                         
  Adju…                                                                         
  Oper…    $        55.5       $   47.9       $       159.3       $   128.6     
  Prof…                                                                         
  Adju…                                                                         
  Oper…                                                                         
  Prof…             22.4  %        20.1  %             21.1  %         18.6  %  
  as a                                                                          
  % of                                                                          
  Sales                                                                         
                                                                                
   See the accompanying Notes to Reconciliation of GAAP to Non-GAAP Financial   
                                    Measures                                    
                                                                                
                                       10                                       
                                                                                
  Adjusted Net Income                                                           
                                                                                
                                                                                
            Three                  Septem…    Nine                              
            Months   October           26,    Months    October       Septemb…  
            Ended    2, 2026          2025    Ended     2, 2026       26, 2025  
 ────────────────────────────────────────────────────────────────────────────── 
  Net                                                                           
  Income    $          508.3    $    -30.3    $           600.7    $      14.1  
  (Loss)                                                                        
  Amort…                                                                        
  of                                                                            
  acqui…                                                                        
  and                   15.0          19.1                 51.2           56.9  
  other                                                                         
  intan…                                                                        
  assets                                                                        
  Restr…                                                                        
  costs                                                                         
  and                    7.9           8.3                 24.2           24.4  
  asset                                                                         
  impai…                                                                        
  Fair                                                                          
  value                                                                         
  adjus…                 0.6           0.6                  1.5            2.0  
  of                                                                            
  acqui…                                                                        
  inven…                                                                        
  Tariff               -15.6             —                -28.2              —  
  refun…                                                                        
  Litig…                   —             —                    —            0.8  
  settl…                                                                        
  Acqui…                   —           0.1                  0.3            0.4  
  expen…                                                                        
  Reali…                                                                        
  cumul…                                                                        
  forei…              -428.1             —               -428.1              —  
  curre…                                                                        
  trans…                                                                        
  gainF                                                                         
  Loss                                                                          
  on                     7.6             —                  9.6              —  
  equity                                                                        
  inves…                                                                        
  Tax                                                                           
  effect                                                                        
  of                   -31.0          -5.3                -41.6          -20.3  
  adjus…                                                                        
  refle…                                                                        
  aboveH                                                                        
  Discr…                                                                        
  tax                                                                           
  adjus…                                                                        
  and                    0.5          61.2                  2.1           60.6  
  other                                                                         
  tax-r…                                                                        
  adjus…                                                                        
  Adjus…                                                                        
  Net       $           65.2    $     53.7    $           191.7    $     138.9  
  Income                                                                        
                                                                                
                                                                                
  Adjusted Diluted Earnings Per Share                                           
                                                                                
                                                                                
            Three                  Septem…    Nine                              
            Months   October           26,    Months    October       Septemb…  
            Ended    2, 2026          2025    Ended     2, 2026       26, 2025  
 ────────────────────────────────────────────────────────────────────────────── 
  Dilut…                                                                        
  Earni…                                                                        
  (Loss)    $           3.11    $    -0.18    $            3.65    $      0.08  
  Per                                                                           
  Share                                                                         
  Amort…                                                                        
  of                                                                            
  acqui…                                                                        
  and                   0.09          0.11                 0.31           0.33  
  other                                                                         
  intan…                                                                        
  assets                                                                        
  Restr…                                                                        
  costs                                                                         
  and                   0.05          0.05                 0.15           0.14  
  asset                                                                         
  impai…                                                                        
  Fair                                                                          
  value                                                                         
  adjus…                   —             —                 0.01           0.01  
  of                                                                            
  acqui…                                                                        
  inven…                                                                        
  Tariff               -0.10             —                -0.17              —  
  refun…                                                                        
  Litig…                   —             —                    —           0.01  
  settl…                                                                        
  Acqui…                   —             —                    —              —  
  expen…                                                                        
  Reali…                                                                        
  cumul…                                                                        
  forei…               -2.62             —                -2.60              —  
  curre…                                                                        
  trans…                                                                        
  gainF                                                                         
  Loss                                                                          
  on                    0.05             —                 0.06              —  
  equity                                                                        
  inves…                                                                        
  Tax                                                                           
  effect                                                                        
  of                   -0.19         -0.03                -0.26          -0.12  
  adjus…                                                                        
  refle…                                                                        
  aboveH                                                                        
  Discr…                                                                        
  tax                                                                           
  adjus…                                                                        
  and                   0.01          0.37                 0.01           0.37  
  other                                                                         
  tax-r…                                                                        
  adjus…                                                                        
  Adjus…                                                                        
  Dilut…                                                                        
  Earni…    $           0.40    $     0.32    $            1.16    $      0.82  
  Per                                                                           
  Share                                                                         
                                                                                
                                       11                                       
                                                                                
  Adjusted Diluted Shares Outstanding                                           
                                                                                
                                                                                
         Thr…  Oct…            Sep…          Nine  Oct…            Sept…        
         Mon…    2,             26,          Mon…    2,              26,        
         End…  2026            2025          End…  2026             2025        
 ────────────────────────────────────────────────────────────────────────────── 
  Av…                                                                           
  co…                                                                           
  st…                                                                           
  sh…          160…            166…                162…            169.2        
  ou…                                                                           
  -                                                                             
  ba…                                                                           
  As…                                                                           
  ex…                                                                           
  of                                                                            
  di…                                                                           
  op…                                                                           
  ve…                                                                           
  of            2.6             1.4                 2.5              1.1        
  di…                                                                           
  re…                                                                           
  st…                                                                           
  and                                                                           
  pe…                                                                           
  st…                                                                           
  un…                                                                           
  Av…                                                                           
  co…                                                                           
  st…                                                                           
  and                                                                           
  co…                163…            167…                164…             170…  
  eq…                                                                           
  sh…                                                                           
  ou…                                                                           
  -                                                                             
  di…                                                                           
                                                                                
Adjusted EBITDA
                                                                                
           Three  Octob…          Sept…       Nine    Octo…          Septe…     
           Mont…      2,            26,       Months     2,             26,     
           Ended    2026           2025       Ended    2026            2025     
 ────────────────────────────────────────────────────────────────────────────── 
  Net                                                                           
  Inco…    $       508.3       $  -30.3       $       600.7       $    14.1     
  (Los…                                                                         
  Inte…                                                                         
  expe…              7.8            9.0                23.9            26.3     
  net                                                                           
  Inco…                                                                         
  tax               -8.1           80.2                26.1           105.5     
  (ben…                                                                         
  expe…                                                                         
  Depr…             10.4           10.1                31.2            30.0     
  Amor…                                                                         
  of                                                                            
  acqu…                                                                         
  and               15.0           19.1                51.2            56.9     
  other                                                                         
  inta…                                                                         
  asse…                                                                         
  Rest…                                                                         
  costs                                                                         
  and                7.9            8.3                24.2            24.4     
  asset                                                                         
  impa…                                                                         
  Fair                                                                          
  value                                                                         
  adju…              0.6            0.6                 1.5             2.0     
  of                                                                            
  acqu…                                                                         
  inve…                                                                         
  Tari…            -15.6              —               -28.2               —     
  refu…                                                                         
  Liti…                —              —                   —             0.8     
  sett…                                                                         
  Acqu…                —            0.1                 0.3             0.4     
  expe…                                                                         
  Real…                                                                         
  cumu…                                                                         
  fore…           -428.1              —               -428…               —     
  curr…                                                                         
  tran…                                                                         
  gainF                                                                         
  Loss                                                                          
  on                 7.6              —                 9.6               —     
  equi…                                                                         
  inve…                                                                         
  Adju…    $       105.8       $   97.1       $       312.4       $   260.4     
  EBIT…                                                                         
  Adju…                                                                         
  EBIT…                                                                         
  as a              15.3  %        14.5  %             14.7  %         13.2  %  
  % of                                                                          
  Sales                                                                         
                                                                                
   See the accompanying Notes to Reconciliation of GAAP to Non-GAAP Financial   
                                    Measures                                    
                                                                                
                                       12                                       
                                                                                
  Core Sales Growth                                                             
                                                                                
1
                                                                                
                                     % Change Three           % Change Nine     
                                       Month Period            Month Period     
                                   Ended October 2,           Ended October     
                                           2026 vs.             2, 2026 vs.     
                                    Comparable 2025         Comparable 2025     
                   Consolidated              Period                  Period     
 ────────────────────────────────────────────────────────────────────────────── 
  Total sales                                   3.2  %                  8.1  %  
  growth                                                                        
  Plus the impact                                                               
  of:                                                                           
  Acquisitions                                 -0.5  %                 -0.5  %  
  Currency                                        —  %                 -2.0  %  
  exchange rates                                                                
  Core Sales                                    2.7  %                  5.6  %  
  Growth                                                                        
  Specialty                                                                     
  Products &                                                                    
  Technologies                                                                  
  Total sales                                   2.8  %                  7.5  %  
  growth                                                                        
  Plus the impact                                                               
  of:                                                                           
  Acquisitions                                 -0.8  %                 -0.8  %  
  Currency                                        —  %                 -2.3  %  
  exchange rates                                                                
  Core Sales                                    2.0  %                  4.4  %  
  Growth                                                                        
  Equipment &                                                                   
  Consumables                                                                   
  Total sales                                   3.9  %                  9.1  %  
  growth                                                                        
  Plus the impact                                                               
  of:                                                                           
  Currency                                      0.2  %                 -1.2  %  
  exchange rates                                                                
  Core Sales                                    4.1  %                  7.9  %  
  Growth                                                                        
                                                                                
1 We use the term “core sales” to refer to GAAP revenue excluding (1) sales from
acquired businesses recorded prior to the first anniversary of the acquisition
(“acquisitions”), (2) sales from discontinued products and (3) the impact of
currency translation. Sales from discontinued products includes major brands or
products that Envista has made the decision to discontinue as part of a
portfolio restructuring. Discontinued brands or products consist of those which
Envista (1) is no longer manufacturing, (2) is no longer investing in the
research or development of, and (3) expects to discontinue all significant sales
within one year from the decision date to discontinue. The portion of sales
attributable to discontinued brands or products is calculated as the net decline
of the applicable discontinued brand or product from period-to-period. The
portion of GAAP revenue attributable to currency exchange rates is calculated as
the difference between (a) the period-to-period change in sales and (b) the
period-to-period change in sales after applying current period foreign exchange
rates to the prior year period. We use the term “core sales growth” to refer to
the measure of comparing current period core sales with the corresponding period
of the prior year.

During the first quarter of 2026, we updated our methodology for how we
calculate changes in the sales price from period to period. Changes in sales
prices are now calculated by comparing the current quarter sales prices to the
full year sales price average from the prior year as it better reflects pricing
trends over time.
                                       13                                       
Reconciliation of Operating Cash Flows to Free Cash Flow
                                                                                
           Three  Octob…          Sept…       Nine    Octo…          Septe…     
           Mont…      2,            26,       Months     2,             26,     
           Ended    2026           2025       Ended    2026            2025     
 ────────────────────────────────────────────────────────────────────────────── 
  Net                                                                           
  oper…                                                                         
  cash                                                                          
  prov…    $        77.9       $   78.7       $       193.8       $   167.7     
  by                                                                            
  oper…                                                                         
  acti…                                                                         
  Less:                                                                         
  paym…                                                                         
  for                                                                           
  addi…                                                                         
  to                                                                            
  prop…            -16.1          -10.8               -43.5           -29.0     
  plant                                                                         
  and                                                                           
  equi…                                                                         
  (cap…                                                                         
  expe…                                                                         
  Plus:                                                                         
  proc…                                                                         
  from                                                                          
  sales                                                                         
  of                 1.7              —                 2.6             0.5     
  prop…                                                                         
  plant                                                                         
  and                                                                           
  equi…                                                                         
  Free                                                                          
  Cash     $        63.5       $   67.9       $       152.9       $   139.2     
  Flow                                                                          
  (FCF)                                                                         
  FCF                                                                           
  to                                                                            
  Adju…                                                                         
  Net               97.4  %       126.4  %             79.8  %        100.2  %  
  Inco…                                                                         
  Conv…                                                                         
  Ratio                                                                         
                                                                                
   See the accompanying Notes to Reconciliation of GAAP to Non-GAAP Financial   
                                    Measures                                    
                                                                                
                                       14                                       
                                                                                
                          ENVISTA HOLDINGS CORPORATION                          
                                                                                
   NOTES TO RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (UNAUDITED)   
A We exclude impairment of certain long-lived assets, executive transition
costs, and cost incurred pursuant to discrete restructuring plans.

B Represents the fair value adjustment related to inventory acquired in
connection with acquisitions.

C Represents the U.S. Supreme Court's ruling to refund tariffs imposed under the
International Emergency Economic Powers Act.

D Represents the settlement of certain litigation matters.

E Represents acquisition-related transaction expenses and integration costs with
respect to business combinations.

F Represents the release of cumulative translation adjustments related to the
dissolution of certain legal entities.

G Represents losses on equity investments.

H This line item represents the aggregate tax effect of all pretax adjustments
reflected in the preceding line items of the table using each adjustment's
applicable tax rate, including the effect of interim tax accounting requirements
of Accounting Standards Codification Topic 740 Income Taxes.

I Discrete tax matters primarily relate to excess tax benefits from stock-based
compensation, changes in estimates associated with prior period uncertain tax
positions and audit settlements, tax benefits resulting from a change in law,
and changes in determination of realization of certain deferred tax assets.

J The Company was in a net loss position for the three months ended September
26, 2025, therefore no shares reserved for issuance upon exercise of stock
options, or vesting of restricted stock and performance stock units were
included in the computation of diluted loss per share as their inclusion would
have been anti-dilutive. However, given that the adjustments noted in footnotes
A-I resulted in adjusted net income for the three months ended September 26,
2025, the dilutive impact of stock options and restricted stock and performance
stock units are being included to arrive at adjusted diluted shares outstanding.
                                                                                
  Statement Regarding Non-GAAP Measures                                         
                                                                                
Each of the non-GAAP measures set forth above should be considered in addition
to, and not as a replacement for or superior to, the comparable GAAP measure,
and may not be comparable to similarly titled measures reported by other
companies. Management believes that these measures provide useful information to
investors by offering additional ways of viewing Envista Holdings Corporation's
(“Envista” or the “Company”) results that, when reconciled to the corresponding
GAAP measure, help our investors to:

• with respect to Core Sales, identify underlying growth trends in Envista’s
business and compare Envista’s revenue performance with prior and future periods
and to Envista’s peers;

• with respect to Adjusted Gross Profit, Adjusted Operating Profit, Adjusted Net
Income, Adjusted Diluted Earnings Per Share and Adjusted EBITDA, understand the
long-term profitability trends of Envista’s business and compare Envista’s
profitability to prior and future periods and to Envista’s peers;

• with respect to Adjusted EBITDA, understand operational factors associated
with Envista’s financial performance because it excludes the following from
consideration: interest, taxes, depreciation, amortization, and infrequent or
unusual losses or gains such as goodwill impairment charges or nonrecurring
items and restructuring charges. Management uses Adjusted EBITDA, as a
supplemental measure for assessing operating performance in conjunction with
related GAAP amounts. In addition, Adjusted EBITDA is used in connection with
operating decisions, strategic planning, annual budgeting, evaluating Company
performance and comparing operating results with historical periods and with
industry peer companies; and
                                       15                                       
• with respect to Free Cash Flow (the “FCF Measure”), understand Envista’s
ability to generate cash without external financings, in order to invest and
grow its business through acquisitions and other strategic opportunities. A
limitation of free cash flow is that it does not take into account the Company’s
debt service requirements and other non-discretionary expenditures, and as a
result the entire Free Cash Flow amount is not necessarily available for
discretionary expenditures.

Management uses these non-GAAP measures to evaluate the Company’s operating and
financial performance.

The items excluded from the non-GAAP measures set forth above have been excluded
for the following reasons:

• With respect to Adjusted Gross Profit, Adjusted Operating Profit, Adjusted Net
Income, Adjusted Diluted Earnings Per Share and Adjusted EBITDA:

◦ We exclude amortization of acquisition-related and other intangible assets
because the amount and timing of such charges are significantly impacted by the
timing, size, number and nature of the acquisitions we consummate. While we have
a history of significant acquisition activity, we do not acquire businesses on a
predictable cycle, and the amount of an acquisition’s purchase price allocated
to intangible assets and related amortization term are unique to each
acquisition and can vary significantly from acquisition to acquisition.
Exclusion of this amortization expense facilitates more consistent comparisons
of operating results over time between our newly acquired and long-held
businesses, and with both acquisitive and non-acquisitive peer companies. We
believe, however, that it is important for investors to understand that such
intangible assets contribute to revenue generation and that intangible asset
amortization related to past acquisitions will recur in future periods until
such intangible assets have been fully amortized.

◦ With respect to the other items excluded from Adjusted Gross Profit, Adjusted
Net Income, Adjusted Operating Profit, Adjusted Diluted Earnings Per Share and
Adjusted EBITDA, we exclude these items because they are of a nature and/or size
that occur with inconsistent frequency, occur for reasons that may be unrelated
to Envista's commercial performance during the period and/or we believe that
such items may obscure underlying business trends and make comparisons of long-
term performance difficult.

• With respect to core sales, we exclude (1) the effect of acquisitions and
divested product lines because the timing, size, number and nature of such
transactions can vary significantly from period-to-period and between us and our
peers, which we believe may obscure underlying business trends and make
comparisons of long-term performance difficult, (2) sales from discontinued
products because discontinued products do not have a continuing contribution to
operations and management believes that excluding such items provides investors
with a means of evaluating our on-going operations and facilitates comparisons
to our peers, and (3) the impact of currency translation because it is not under
management’s control, is subject to volatility and can obscure underlying
business trends.

• With respect to the FCF Measure, we adjust for payments for additions to
property, plant and equipment (net of the proceeds from capital disposals) to
arrive at the amount of operating cash flow for the period that remains after
accounting for the Company’s capital expenditure requirements.
                                       16                                       

Sources

The 8-K item 2.02 filings (SEC EDGAR) and their EX-99 exhibits: the results release and, when filed, prepared remarks or the call transcript.

Also

Said vs did: the targets in these releases against what was then reported. Filings: every filing.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/NVST/export.csv") into a cell.

Next:Presentations
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.